Key facts
- This page summarizes Robert Benjamin Stein's Form 4 filing for MIMEDX GROUP, INC. (MDXG).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 May 2023, 18:26.
Robert Benjamin Stein - 15 May 2023 Form 4 Insider Report for MIMEDX GROUP, INC. (MDXG)
- Reporting relationship
- President, Regenerative Med.
- Issuer ticker
- MDXG
- Reported as of
- 15 May 2023
- Net transaction value
- -$83,798
- SEC form
- 4
- Accepted by SEC
- 17 May 2023, 18:26:21 UTC
- Prior SEC filing
- 12 May 2023
- Next SEC filing
- 29 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ William F. Hulse as attorney in fact for Robert Benjamin Stein
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Benjamin Stein filed Form 4 for MIMEDX GROUP, INC. (MDXG) on 17 May 2023.
Change
- Previous filing in this sequence was filed on 12 May 2023.
- Current net transaction value: -$83,798.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDXG
transaction
Common Stock
Sale
- Transaction value
- $22,170
- Shares
- -3,607
- Change %
- -1.1%
- Price
- $6.15
- Shares after
- 328,168
- Date
- 15 May 2023
- Ownership
- Direct
- Footnotes
- F1
MDXG
transaction
Common Stock
Sale
- Transaction value
- $61,627
- Shares
- -10,365
- Change %
- -3.2%
- Price
- $5.95
- Shares after
- 317,803
- Date
- 16 May 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $6.120 to $6.190, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein.
Footnote F2
The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $5.870 to $6.025, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein.